

RECEIVED

AUG 02 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Here application of

Yasuhiro FUKAGAWA et al.

Serial No. 09/284,578

Filed October 8, 1999

:

Docket No. 00325/CH:MKK,PC/E-6-627US

: Group Art Unit 1617

: Examiner E. Webman

BIOLOGICALLY ACTIVE POLYMER
PRODUCTS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of ☒ the references listed on attached form PTO-1449 and/or ☐ the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 is enclosed.

1a. ☐ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing date of the first Office Action on the merits,

and thus no certification and/or fee is required.

1b. ☒ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, or

(2) ☒ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:

a. ☐ a full or partial English language translation submitted herewith,

b. ☐ a foreign patent office search report (in the English language) submitted herewith,

c. ☐ the concise explanation contained in the specification of the present application at page,

- d. ☒ the concise explanation set forth in the attached English language abstract,
- e. ☒ the concise explanation set forth below or on a separate sheet attached to the reference:

JP 1-16389 discloses that a polymyxin which is a cyclic peptide antibiotic substance is immobilized in an insoluble carrier to give an endotoxin adsorbent. The immobilized polymyxin acts as adsorbent to endotoxin, which is adsorbed on immobilized polymyxin. That is, endotoxin can be adsorbed on either a carrier portion or polymyxin moiety which is bonded to the carrier.

In addition, JP '389 does not disclose any specific position in the polymyxin and carrier molecules at which the polymyxin should be bonded to the carrier. That is, polymyxin can be bonded to the carrier at any positions in the molecule without giving rise to any essential change in adsorption ability.

5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Yasuo FUKAGAWA et al.

By 

Michael R. Davis

Registration No. 25,134

Attorney for Applicants

MRD/aeh
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 30, 2001

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975